| answer text |
<p>The Government has assessed the link between the cap mechanism in our medicine
pricing schemes and various kinds of investment in our impact assessment of recent
updates to the statutory scheme for branded medicines pricing, which operates alongside
the voluntary scheme for branded medicines pricing and access (VPAS). The Government’s
2023 impact assessment of updates to the statutory scheme is available at the following
link:</p><p><a href="https://www.gov.uk/government/consultations/proposed-update-to-the-2023-statutory-scheme-to-control-the-costs-of-branded-health-service-medicines"
target="_blank">https://www.gov.uk/government/consultations/proposed-update-to-the-2023-statutory-scheme-to-control-the-costs-of-branded-health-service-medicines</a></p><p>The
Government is working to better understand the impacts the operation of the current
VPAS on the United Kingdom’s life sciences industry. We are in direct conversations
with pharmaceutical companies, including in the recent pre-negotiation workshops,
as well as the Department for Science Innovation and Technology, and Department for
Business and Trade about the business environment for life sciences.</p><p>Controlling
medicine spend is a key departmental aim for both current and future schemes to improve
patient outcomes by simplifying, streamlining, and improving access, pricing, and
uptake arrangements for cost effective medicines, and deliver faster adoption of most
clinically and cost-effective medicines.</p>
|
|
